Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/ HER2-negative breast cancer

被引：0
|
作者：
Ahn, S. G. [1 ]
Cha, Y. J. [2 ]
Yoon, C. [1 ]
Bae, S. J. [1 ]
Kim, J. [3 ]
Jeong, J. [1 ]
机构：
[1] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Surg, Seoul, South Korea
[2] Gangnam Severance Hosp, Pathol, Seoul, South Korea
[3] Kangnam Mizmedi Hosp, Surg, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    [J]. CANCER RESEARCH, 2017, 77
  • [32] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    [J]. CANCER RESEARCH, 2011, 71
  • [33] META-ANALYSIS OF PROSPECTIVE EUROPEAN STUDIES ASSESSING THE IMPACT OF USING THE 21-GENE RECURRENCE SCORE ASSAY ON CLINICAL DECISION MAKING IN WOMEN WITH ER-POSITIVE, HER2-NEGATIVE EARLY STAGE BREAST CANCER
    Albanell, J.
    Holt, S.
    Gligorov, J.
    Eiermann, W.
    Svedman, C.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 97 - 97
  • [34] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Weiser, Roi
    Haque, Waqar
    Polychronopoulou, Efstathia
    Hatch, Sandra S.
    Kuo, Yong-fang
    Gradishar, William J.
    Klimberg, V. Suzanne
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 667 - 676
  • [35] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Roi Weiser
    Waqar Haque
    Efstathia Polychronopoulou
    Sandra S. Hatch
    Yong-fang Kuo
    William J. Gradishar
    V. Suzanne Klimberg
    [J]. Breast Cancer Research and Treatment, 2021, 185 : 667 - 676
  • [36] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [37] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [38] The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer
    Oikawa, Masahiro
    Ishida, Mayumi
    Nakamura, Yoshiaki
    Nishimura, Sumiko
    Koga, Chinami
    Saruwatari, Akihiro
    Igawa, Akiko
    Akiyoshi, Sayuri
    Koi, Yumiko
    Ohno, Shinji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
  • [40] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
12345